Diamonds and Dogs
1/2/15
Brainstorm Therapeutics is making its investors look like geniuses today, up 56.72% to $7.46. The adult stem cell therapy company saw its shares take off prior to their Monday announcement of their ALS trials. Brainstorm plans to release the final results from its Phase 2a trial of its stem cell therapy NurOwn. The company describes NurOwn as an "autologous, adult stem cell therapy technology." Shares of Brainstorm climbed up over $2.70 per share today to a new 52-week high of $8.47 intraday.
MiMedx Group Inc. (MDXG)
MiMedx is starting 2015 on a bad note, down 15.52% to $9.74. The bio-tissue processing company saw its shares fall after announce a subpoena and a counter lawsuit. Management stated that it received a subpoena regarding its marketing activities and it has sued competitor Organogenesis over claims of business interference. CEO Parker H. Petit said, "I can assure you that the corporate officers at MiMedx are not aware of anything that would stimulate this investigation." Shares of MiMedx fell around $1.80 today, but are still above their 52-week low of $4.88.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.